Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1ΞΊ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 114
- Registration Number
- NCT02616640
- Locations
- πΊπΈ
Local Institution - 108, Boston, Massachusetts, United States
πΊπΈLocal Institution - 115, Boston, Massachusetts, United States
πͺπΈLocal Institution - 504, Madrid, Spain
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02563925
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 153
- Registration Number
- NCT02537418
- Locations
- π¨π¦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
π¨π¦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
π¨π¦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Adjuvant Durvalumab for Esophageal Cancer
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 86
- Registration Number
- NCT02520453
- Locations
- π°π·
Samsung Medical Center, Seoul, MA, Korea, Republic of
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 433
- Registration Number
- NCT02519348
- Locations
- π¨π³
Research Site, Taoyuan City, Taiwan
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 192
- Registration Number
- NCT02503774
- Locations
- π°π·
Research Site, Seoul, Korea, Republic of
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT02492867
- Locations
- πΊπΈ
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States
πΊπΈUniversity of Michigan Cancer Center, Ann Arbor, Michigan, United States
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
- Conditions
- Interventions
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 384
- Registration Number
- NCT02484404
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 53
- Registration Number
- NCT02431559
- Locations
- πΊπΈ
Research Facitlity, Phoenix, Arizona, United States
π¨πResearch Facility, Lausanne, Switzerland
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 124
- Registration Number
- NCT02403271
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.